to better understand how to utilize currently approved COVID-19 vaccines in people living with HIV in order to achieve the most potent and long-lived immune responses | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2022
Known Financial Commitments (USD)
$3,817,329
Funder
Gates Foundation
Research Location
South Africa
Lead Research Institution
Wits Health Consortium (Pty) Ltd
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Individuals with multimorbidity, Other
Occupations of Interest
Unspecified

Abstract

N/A

3 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

HLA typing of HLA-A, -B, -C, -DPB1, -DQB1 and -DRB1 loci of 226 individuals from three metropolitan areas in South Africa.

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Authors
Riou C, Bhiman JN, Ganga Y, Sawry S, Ayres F, Baguma R, Balla SR, Benede N, Bernstein M, Besethi AS, Cele S, Crowther C, Dhar M, Geyer S, Gill K, Grifoni A, Hermanus T, Kaldine H, Keeton RS, Kgagudi P, Khan K, Lazarus E, Le Roux J, Lustig G, Madzivhandila M, Magugu SFJ, Makhado Z, Manamela NP, Mkhize Q, Mosala P, Motlou TP, Mutavhatsindi H, Mzindle NB, Nana A, Nesamari R, Ngomti A, Nkayi AA, Nkosi TP, Omondi MA, Panchia R, Patel F, Sette A, Singh U, van Graan S, Venter EM, Walters A, Moyo-Gwete T, Richardson SI, Garrett N, Rees H, Bekker LG, Gray G, Burgers WA, Sigal A, Moore PL, Fairlie L.
Publish Year
2024
Journal
PLOS global public health
DOI
10.1371/journal.pgph.0002703

View at Europe PMC

Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant.